SAB Biotherapeutics, Inc. (SABSW) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Sioux Falls, SD, 미국. 현재 CEO는 Samuel J. Reich.
SABSW 을(를) 보유 IPO 날짜 2021-10-25, 63 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $238.95K.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
